Source: Virtual Congress 2021 – Hot topics in thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. Vermaelen (Ghent, Belgium). Checkpoint inhibition (neo-)adjuvant therapy in early stage lung cancer: the oncological evidence. Virtual Congress 2021 – Hot topics in thoracic oncology

Member's Comments

No comment yet.

Related content which might interest you: Current neoadjuvant/adjuvant treatment for advanced stage lung cancer Source: International Congress 2014 – PG19 Surgery for advanced stage lung cancer Year: 2014 Early stage nonsmall-cell lung cancer: therapeutic options (surgery, adjuvant and neoadjuvant therapy) Source: Annual Congress 2011 - PG10 Management of thoracic tumours in practice: a HERMES basic course Year: 2011 Role of adjuvant/neoadjuvant treatment in stage I NSCLC Source: International Congress 2014 – Current therapeutic options in stage I non-small cell lung cancer (NSCLC) Year: 2014 Effect of adjuvant chemotherapy on lung function in early stage NSCLC Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients Year: 2011 Survival and postoperative complication after neoadjuvant therapy in resectable stage IIIA-N2 non-small cell lung cancer: a balancing exercise Source: Eur Respir J 2003; 22: Suppl. 45, 31s Year: 2003 Neo-adjuvant chemotherapy: level of evidence in early stage and in marginally resectable disease Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005 Impact of neoadjuvant therapies on surgical indications and early postoperative outcome Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005 Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction? Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer Year: 2006 The correlation between clinical and pathomorphological impacts of induction chemotherapy and long-term results of multimodality treatment for IIIA stage non-small cell lung cancer Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Neoadjuvant chemotherapy for NSCLC, lung function and surgical therapy – which is their connection? Source: International Congress 2019 – Lung function testing: from experimental investigations to clinical applications Year: 2019 Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer Source: Eur Respir J 2013; 42: 1119-1133 Year: 2013 Is there any place for perioperative radiation therapy? Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts Year: 2005 Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Treatment of potentially resectable locoregional (stage III) non-small cell lung cancer Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment Year: 2005 Impact of neoadjuvant therapy on tumor resectability and survival of patients with locally advanced non-small cell lung cancer Source: Annual Congress 2011 - General thoracic surgery II Year: 2011 Can molecular markers (EGFR, ERCC1) serve as screening parameters for adjuvant chemotherapy decision in early staged non-small cell lung cancer patients? Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Stage I-IIIa small cell lung cancer (SCLC): multimodal therapy including surgery Source: Eur Respir J 2001; 18: Suppl. 33, 318s Year: 2001 Treatment of non-microcelular lung cancer in its advanced stage Source: Annual Congress 2008 - Treatment of thoracic tumours Year: 2008